N eutrophil gelatinase-associated lipocalin (NGAL) is a glycoprotein stored in granules of neutrophil leukocytes. 1 In response to cellular stress, NGAL is rapidly released by hepatocytes, endothelial and smooth muscle cells, renal tubular cells, and activated neutrophils.
Clinical use of NGAL has until recently focused on its role as a marker of acute kidney injury (AKI) because especially urinary NGAL is a sensitive and early marker of AKI preceding serum creatinine elevation with ≈48 to 72 hours. 2, 3 However, lately attention has focused on NGAL in cardiovascular disease (CVD).
NGAL was originally identified as part of the innate immune system, mediating inflammatory activity through binding to chemotactic peptides, leukotrienes, and platelet-activating factor. 4, 5 NGAL is upregulated in endothelial dysfunction and inflammatory vascular damage. 6, 7 Furthermore NGAL is highly expressed in atheromatous plaques and correlated with characteristics of unstable plaques: infiltrating inflammatory cells, thrombus formation, plaque hemorrhage, and central necrosis. 8, 9 Through formation of a complex with metalloproteinase-9 (MMP-9), an important mediator of vascular remodeling and plaque instability, NGAL may also play an important role in plaque rupture.
Results
The median plasma level of NGAL was 202 μg/L (interquartile range: 158-265) and similar across sex (203 μg/L in men versus 201 in women; P=0. 10) . The 95% range of NGAL concentrations was from 100 to 498 μg/L. During the 10 years follow-up, 1120 participants died (20%) and 864 (15%) reached the combined end point of major adverse cardiovascular event (MACE). Table 1 describes baseline characteristics according to quartiles of plasma NGAL. Associations between NGAL, inflammatory biomarkers, and estimated glomerular filtration rate (eGFR) are shown in Figure 1 . As seen, plasma NGAL associated strongly with all 3 markers of inflammation and inversely with eGFR (all, P<0.001).
Baseline Characteristics
NGAL levels were increased slightly in participants with a history of CVD, median (interquartile range) 218 (210-226) versus 205 (200-211), P<0.001. By contrast, NGAL levels were similar in patients with prevalence of traditional cardiovascular risk factors (diabetes mellitus, hypertension, hypercholesterolemia, and smoking; Table 2 ).
In a multivariate model including all variables, NGAL associated positively with age, male sex, alcohol consumption, high-sensitivity C-reactive protein (hcCRP), and neutrophil leukocyte count and inversely with eGFR (all, P<0.001). Neutrophil leukocyte count was the main predictor of plasma NGAL; a doubling in neutrophil leukocyte count associated with an increase in NGAL of 34% (29%-39%). eGFR appeared to associate closer with NGAL when eGFR was reduced (≤60 mL/min; Figure 1 ). This was confirmed using cubic regression splines (P<0.001). Importantly this nonlinear association between NGAL and eGFR significantly affected the association between eGFR and NGAL; when eGFR was reduced (≤60 mL/ min), a decrease of 10 in eGFR associated with an increase in NGAL of 13% (9%-18%). By comparison, a decrease of 10 in eGFR only associated with an NGAL increase of 3% (2%-4%) when eGFR was in the normal range. Weaker associations were seen with a history of CVD and body mass index. Of interest, NGAL did not associate with plasma proBNP (P=0.23).
NGAL and Outcome
Kaplan-Meier curves demonstrated a significant association between quartiles of plasma NGAL and all-cause mortality and MACE (Figure 2) . The association between log-transformed NGAL and both end points was examined in both univariable and several multivariable Cox regression analyses (Table 3) 
NGAL and hsCRP
To compare the prognostic value of NGAL to hsCRP, we divided patients into groups based on hsCRP and NGAL using the standard cutoffs for hsCRP (1 and 2 mg/L) and >75th percentile for NGAL (264.9 μg/mL). Participants were then sorted by high/low hsCRP and high/low NGAL. Table 4 shows a Cox regression model estimating the risk between the 4 groups. As seen, the risk of both all-cause mortality and MACE doubled in patients with high NGAL and low hsCRP. In comparison, elevated hsCRP conferred slightly less increased risk. When both markers were high, the risk for both outcomes about tripled. Figure 3 depicts Kaplan-Meier curves for risk of MACE for the 4 groups. As shown, high hsCRP/high NGAL had the worst outcomes, whereas participants with low levels of both markers had the best prognosis.
When adding both markers to the Framingham risk score, a doubling in NGAL associated with increased risk of all-cause mortality (HR: 
Reclassification
To address the clinical application of NGAL, we calculated how many patients were reclassified after the addition of NGAL to one of the currently used risk scores for both end points (all-cause mortality and MACE). Table 5 presents the proportion of patients initially classified as having a 10-year risk of <5%, 5% to 10%, 10% to 20%, 20% to 30%, and >30% based on the Framingham risk score, who would be reclassified to either higher or lower risk categories by the addition of NGAL.
As shown for all-cause mortality (Table 5) , the proportion of patients reclassified was relatively low for participants with a 10-year risk of <10% (9%). However, 19% and 25% of all patients estimated to be at 10% to 20% or at 20% to 30% using the Framingham risk score were reclassified into higher or lower risk categories. Table 4 also shows that actual event rates matched well with the predicted in almost all risk categories; a total of 665 (13%) patients were reclassified, of which 525 (79%) were placed into more accurate risk categories. Table 6 presents similar analyses for the end point MACE. As shown, 34% of all patients with an estimated 10-year risk of MACE of 20% to 30% according to the Framingham risk score were reclassified after the addition of NGAL. There was almost perfect matching of observed and predicted risks after the addition of NGAL; of the 771 (16%) patients reclassified, all but 27 were placed into more accurate risk categories.
Discussion
In brief, the present study shows for the first time that the main determinant of plasma NGAL in the general population is neutrophil leukocyte count, whereas kidney function contributes less. The main finding is that during 10-year follow-up, NGAL independently associates with both all-cause mortality and MACE. Compared with the established inflammatory biomarker hsCRP, NGAL conferred more risk. NGAL is a small, 25-kDa glycoprotein belonging to the lipocalin superfamily and located in neutrophilic granules. 1 It acts as a scavenger in inflamed areas and modulates inflammation through binding to chemotaxic peptides. [15] [16] [17] However, the central part of NGAL in atherosclerosis seems centered on MMP-9, an endopeptidase responsible for cellular degrading in atherosclerotic plaques. 10, 18 NGAL inhibits MMP-9 inactivation by forming a complex with MMP-9, thereby prolonging the proteolytic activity leading to decreased collagen content, weakening the plaque structure, and making it more prone to rupture, which is the main cause of myocardial infarction. 11, 19, 20 Recently, Hemdahl et al 11 demonstrated increased NGAL expression in atherosclerotic plaques and colocalization with MMP-9 especially in areas with high proteolytic activity. In patients with abdominal aortic aneurism and thus intraluminal thrombus formation, neutrophils released twice the amount of NGAL as in healthy controls. 21 In heart failure (HF), NGAL expression increased in cardiomyocytes in the failing myocardium, and through MMP-9, NGAL may possibly be involved in myocardial remodeling. 19 Our finding of an incremental association between NGAL and cardiovascular outcome further supports a role of NGAL in atherosclerosis.
We were able to show that in the general population neutrophil leukocytes were the main determinant of plasma NGAL. Although eGFR was still independently associated with NGAL, the contribution to NGAL levels was relatively small. These results confirm that plasma NGAL in a healthy population mainly reflects inflammation and not chronic kidney disease as opposed to urinary NGAL. 22 Although NGAL was strongly associated with other markers of inflammation, it still added prognostic value beyond the established inflammatory marker hsCRP, indicating that NGAL complements information on vascular inflammation. By contrast, Helmersson-Karlqvist et al 22 did not find an association between plasma NGAL and outcome in 597 older adults when adjusting for CRP. However, this may be because of a nonstandardized handling of blood samples, resulting in increased variability in plasma NGAL.
22
NGAL has been demonstrated efficient in predicting AKI 24 to 72 hours before creatinine increase in critically ill patients and patients undergoing cardiac surgery. 2, 3, 23 However, there are several indications that urinary NGAL may be a more specific marker of AKI compared with plasma NGAL. During ischemic and toxic renal injury, both synthesis and secretion of NGAL are upregulated in the proximal tubules of the distal nephron, resulting in a massive increase in urinary NGAL. 2, 24 By contrast, the contribution to plasma NGAL from the kidney has been questioned, and the main source of plasma NGAL is suggested to come from activated neutrophils. 25, 26 Our results clearly support this theory; however, AKI is not supposed to be present in our study because we investigated participants from the community. In fact, eGFR was high (median 80 mL/min [70-91 mL/ min]), and only 11% (n=605) of the participants had a reduced eGFR (<60 mL/min). It is possible, that the association between plasma NGAL and eGFR could be stronger in a population with a lower kidney function. Also, we did not have measurements of urinary NGAL, which would have been interesting to compare with plasma NGAL as done by Helmersson-Karlqvist et al. 22 Still, from our results, it is tempting to hypothesize that in critically ill patients with an increased inflammatory response (such as sepsis, cancer, myocardial infarction), plasma NGAL may reflect both the systemic inflammation, as well as possible AKI. However, more research is needed before firm conclusions can be drawn.
It is of interest that NGAL did not associate with proBNP, which currently is the golden standard prognostic marker in CVD. ProBNP reflects myocardial wall stress and is strongly correlated with hypertension, whereas NGAL supposedly mediates vascular damage and plaque rupture. 27 Thus the 2 markers reflect distinct pathophysiological mechanisms of CVD. An association between the 2 markers has previously been described in HF. 27, 29 However, our finding that plasma NGAL is not associated with proBNP is in agreement with Daniels et al 30 from the Rancho Bernard Study. In that study, plasma NGAL added prognostic value beyond and above NT-proBNP (N-terminal proBNP) in 1393 community-dwelling older adults. Recent studies suggest that NGAL is a strong marker of outcome in patients with acute myocardial infarction and HF. 31, 32 We have also shown this in 584 patients with ST-segmentelevation myocardial infarction.
14 In 186 patients with acute HF, Maisel et al 31 demonstrated that NGAL added to the predictive value of proBNP, with the worst outcome occurring in the group with high NGAL and high proBNP; in fact NGAL at discharge was an even stronger predictor of readmission and all-course mortality than proBNP. 31 It could be a significant finding that the 2 biomarkers do not correlate, reflect different pathophysiological mechanisms, and are both elevated in CVD.
In conclusion, plasma NGAL is associated to biomarkers of inflammation and independently predicts mortality and MACE adding incremental value to traditional cardiovascular risk factors and hsCRP.
Study Limitations and Strengths
The present findings are based on an epidemiological approach including the use of nationwide registries for ascertainment of MACE. Although highly validated, these findings cannot show causality. Body mass index in this Danish cohort from the General population was relatively low (25.9±3.4) compared with similar cohorts from US or other European countries. Accordingly, results may not be generalizable. Blood samples were collected during a 2-year period from 2001 to 2003. It is possible that the absolute concentration of NGAL has increased a little over time because blood samples are >10 years old; however, it is unlikely that this has affected our results because all samples have been treated in the same way in terms of freezing/thawing and storage.
Study strengths include the longitudinal community-based study design with 10 years follow-up, which to date is the largest study with measurements of plasma NGAL. In addition, no participants were lost to follow-up because of the high quality Danish registry data.
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